European Commission Approves Shionogi's Zokovea for COVID-19 Post-Exposure Prophylaxis

The European Commission has granted marketing authorization for Shionogi & Co., Ltd.'s Zokovea (ensitrelvir) for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older. This makes Zokovea the first oral antiviral medicine authorized in the European Union for this indication.